Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) EPS (Weighted Average and Diluted) (2020 - 2025)

VYNE Therapeutics (VYNE) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.14 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EPS (Weighted Average and Diluted) rose 36.36% year-over-year to -$0.14, compared with a TTM value of -$0.0 through Dec 2025, up 99.94%, and an annual FY2025 reading of -$0.62, up 33.33% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.14 for Q2 2025 at VYNE Therapeutics, up from -$0.2 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $4.1 in Q4 2023 and bottomed at -$14.24 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.58, with a median of -$0.34 recorded in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 322.68% in 2023, while the deepest fall reached 2092.86% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$14.24 in 2021, then surged by 106.81% to $0.97 in 2022, then soared by 322.68% to $4.1 in 2023, then tumbled by 106.59% to -$0.27 in 2024, then skyrocketed by 48.15% to -$0.14 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for VYNE at -$0.14 in Q2 2025, -$0.2 in Q1 2025, and -$0.27 in Q4 2024.